PARIS MANDY: Open Payments
NPI 1205502283 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,207 in 130 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $359 · 2025 $3,207
Food & beverage: $3,207
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $845 |
| Alkermes, Inc. | 13 | $370 |
| E.R. Squibb & Sons, L.L.C. | 9 | $366 |
| Vanda Pharmaceuticals Inc. | 11 | $313 |
| Corium, LLC | 12 | $311 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $179 |
| Neurocrine BioSciences, Inc. | 6 | $157 |
| Teva Pharmaceuticals USA, Inc. | 9 | $136 |
| Janssen Pharmaceuticals, Inc | 6 | $132 |
| Axsome Therapeutics, Inc. | 6 | $127 |
Products named: VRAYLAR, COBENFY, FANAPT, Azstarys, ARISTADA, LYBALVI, CAPLYTA, INGREZZA.
Industry payments across AZ — which companies pay providers there.
